{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T06:35:52Z","timestamp":1768286152103,"version":"3.49.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,1,21]]},"DOI":"10.7759\/cureus.77795","type":"journal-article","created":{"date-parts":[[2025,1,21]],"date-time":"2025-01-21T23:58:57Z","timestamp":1737503937000},"source":"Crossref","is-referenced-by-count":2,"title":["Significance of Neutrophil-to-Lymphocyte Ratio in Predicting the Efficacy of Anamorelin for Cancer Cachexia"],"prefix":"10.7759","author":[{"given":"Yusuke","family":"Nakazawa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kanako","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ako","family":"Gannichida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tadashi","family":"Uwagawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takashi","family":"Kawakubo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"crossref","DOI":"10.1016\/S1470-2045(10)70218-7","article-title":"Definition and classification of cancer cachexia: an international consensus","volume":"12","author":"Fearon K","year":"2011","unstructured":"Fearon K, Strasser F, Anker SD, et al.. Definition and classification of cancer cachexia: an international consensus. Lancet Oncol. 2011, 12:489-95.","journal-title":"Lancet Oncol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1007\/s13539-012-0087-1","article-title":"Cancer cachexia: impact, mechanisms and emerging treatments","volume":"4","author":"Vaughan VC","year":"2013","unstructured":"Vaughan VC, Martin P, Lewandowski PA. Cancer cachexia: impact, mechanisms and emerging treatments. J Cachexia Sarcopenia Muscle. 2013, 4:95-109. 10.1007\/s13539-012-0087-1","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-009-0684-5","article-title":"A descriptive review of the factors contributing to nutritional compromise in patients with head and neck cancer","volume":"17","author":"Chasen MR","year":"2009","unstructured":"Chasen MR, Bhargava R. A descriptive review of the factors contributing to nutritional compromise in patients with head and neck cancer. Support Care Cancer. 2009, 17:1345-51. 10.1007\/s00520-009-0684-5","journal-title":"Support Care Cancer"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpainsymman.2012.06.020","article-title":"Psychosocial effects of cancer cachexia: a systematic literature search and qualitative analysis","volume":"46","author":"Oberholzer R","year":"2013","unstructured":"Oberholzer R, Hopkinson JB, Baumann K, Omlin A, Kaasa S, Fearon KC, Strasser F. Psychosocial effects of cancer cachexia: a systematic literature search and qualitative analysis. J Pain Symptom Manage. 2013, 46:77-95. 10.1016\/j.jpainsymman.2012.06.020","journal-title":"J Pain Symptom Manage"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.clnu.2016.07.015","article-title":"ESPEN guidelines on nutrition in cancer patients","volume":"36","author":"Arends J","year":"2017","unstructured":"Arends J, Bachmann P, Baracos V, et al.. ESPEN guidelines on nutrition in cancer patients. Clin Nutr. 2017, 36:11-48. 10.1016\/j.clnu.2016.07.015","journal-title":"Clin Nutr"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdu085","article-title":"Early recognition of malnutrition and cachexia in the cancer patient: a position paper of a European School of Oncology Task Force","volume":"25","author":"Aapro M","year":"2014","unstructured":"Aapro M, Arends J, Bozzetti F, et al.. Early recognition of malnutrition and cachexia in the cancer patient: a position paper of a European School of Oncology Task Force. Ann Oncol. 2014, 25:1492-9. 10.1093\/annonc\/mdu085","journal-title":"Ann Oncol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdu178","article-title":"'Pre-cachexia': a non-existing phenomenon in cancer?","volume":"25","author":"Blauwhoff-Buskermolen S","year":"2014","unstructured":"Blauwhoff-Buskermolen S, de van der Schueren MA, Verheul HM, Langius JA. 'Pre-cachexia': a non-existing phenomenon in cancer?. Ann Oncol. 2014, 25:1668-9. 10.1093\/annonc\/mdu178","journal-title":"Ann Oncol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-014-2534-3","article-title":"Prognostic impact of cancer cachexia in patients with advanced non-small cell lung cancer","volume":"23","author":"Kimura M","year":"2015","unstructured":"Kimura M, Naito T, Kenmotsu H, et al.. Prognostic impact of cancer cachexia in patients with advanced non-small cell lung cancer. Support Care Cancer. 2015, 23:1699-708. 10.1007\/s00520-014-2534-3","journal-title":"Support Care Cancer"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.12788\/jcso.0133","article-title":"Health professionals' attitudes toward the detection and management of cancer-related anorexia-cachexia syndrome, and a proposal for standardized assessment","volume":"13","author":"Del Fabbro E","year":"2015","unstructured":"Del Fabbro E, Jatoi A, Davis M, Fearon K, di Tomasso J, Vigano A. Health professionals' attitudes toward the detection and management of cancer-related anorexia-cachexia syndrome, and a proposal for standardized assessment. J Community Support Oncol. 2015, 13:181-7. 10.12788\/jcso.0133","journal-title":"J Community Support Oncol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1172\/JCI13300","article-title":"Hypothalamic growth hormone secretagogue receptor regulates growth hormone secretion, feeding, and adiposity","volume":"109","author":"Shuto Y","year":"2002","unstructured":"Shuto Y, Shibasaki T, Otagiri A, et al.. Hypothalamic growth hormone secretagogue receptor regulates growth hormone secretion, feeding, and adiposity. J Clin Invest. 2002, 109:1429-36. 10.1172\/JCI13300","journal-title":"J Clin Invest"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1007\/s13539-014-0159-5","article-title":"Anamorelin HCl (ONO-7643), a novel ghrelin receptor agonist, for the treatment of cancer anorexia-cachexia syndrome: preclinical profile","volume":"5","author":"Pietra C","year":"2014","unstructured":"Pietra C, Takeda Y, Tazawa-Ogata N, Minami M, Yuanfeng X, Duus EM, Northrup R. Anamorelin HCl (ONO-7643), a novel ghrelin receptor agonist, for the treatment of cancer anorexia-cachexia syndrome: preclinical profile. J Cachexia Sarcopenia Muscle. 2014, 5:329-37. 10.1007\/s13539-014-0159-5","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.31128","article-title":"Anamorelin (ONO-7643) for the treatment of patients with non-small cell lung cancer and cachexia: results from a randomized, double-blind, placebo-controlled, multicenter study of Japanese patients (ONO-7643-04)","volume":"124","author":"Katakami N","year":"2018","unstructured":"Katakami N, Uchino J, Yokoyama T, et al.. Anamorelin (ONO-7643) for the treatment of patients with non-small cell lung cancer and cachexia: results from a randomized, double-blind, placebo-controlled, multicenter study of Japanese patients (ONO-7643-04). Cancer. 2018, 124:606-16. 10.1002\/cncr.31128","journal-title":"Cancer"},{"key":"ref13","doi-asserted-by":"crossref","DOI":"10.1016\/S1470-2045(15)00558-6","article-title":"Anamorelin in patients with non-small-cell lung cancer and cachexia (ROMANA 1 and ROMANA 2): results from two randomised, double-blind, phase 3 trials","volume":"17","author":"Temel JS","year":"2016","unstructured":"Temel JS, Abernethy AP, Currow DC, Friend J, Duus EM, Yan Y, Fearon KC. Anamorelin in patients with non-small-cell lung cancer and cachexia (ROMANA 1 and ROMANA 2): results from two randomised, double-blind, phase 3 trials. Lancet Oncol. 2016, 17:519-31.","journal-title":"Lancet Oncol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmet.2012.06.011","article-title":"Cancer cachexia: mediators, signaling, and metabolic pathways","volume":"16","author":"Fearon KC","year":"2012","unstructured":"Fearon KC, Glass DJ, Guttridge DC. Cancer cachexia: mediators, signaling, and metabolic pathways. Cell Metab. 2012, 16:153-66. 10.1016\/j.cmet.2012.06.011","journal-title":"Cell Metab"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1101\/gad.276733.115","article-title":"Mechanisms of metabolic dysfunction in cancer-associated cachexia","volume":"30","author":"Petruzzelli M","year":"2016","unstructured":"Petruzzelli M, Wagner EF. Mechanisms of metabolic dysfunction in cancer-associated cachexia. Genes Dev. 2016, 30:489-501. 10.1101\/gad.276733.115","journal-title":"Genes Dev"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijsu.2018.03.051","article-title":"Role of liver resection in treating intermediate and advanced stage adolescent and young adult hepatocellular carcinoma patients: a propensity-matching cohort study","volume":"54","author":"Zhang W","year":"2018","unstructured":"Zhang W, Liu C, Tan Y, Jiang L, Yan L, Yang J, Wen T. Role of liver resection in treating intermediate and advanced stage adolescent and young adult hepatocellular carcinoma patients: a propensity-matching cohort study. Int J Surg. 2018, 54:259-64. 10.1016\/j.ijsu.2018.03.051","journal-title":"Int J Surg"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2021-1304","article-title":"Prognostic significance of baseline neutrophil-lymphocyte ratio in patients with non-small-cell lung cancer: a pooled analysis of open phase III clinical trial data","volume":"18","author":"Huang L","year":"2022","unstructured":"Huang L, Jiang S, Shi Y. Prognostic significance of baseline neutrophil-lymphocyte ratio in patients with non-small-cell lung cancer: a pooled analysis of open phase III clinical trial data. Future Oncol. 2022, 18:1679-89. 10.2217\/fon-2021-1304","journal-title":"Future Oncol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.1105587","article-title":"Pretreatment neutrophil to lymphocyte ratio as prognostic factor in metastatic breast cancer treated with cyclin dependent kinase 4\/6 inhibitors","volume":"12","author":"Rottier P","year":"2022","unstructured":"Rottier P, Emile G, Johnson A, et al.. Pretreatment neutrophil to lymphocyte ratio as prognostic factor in metastatic breast cancer treated with cyclin dependent kinase 4\/6 inhibitors. Front Oncol. 2022, 12:1105587. 10.3389\/fonc.2022.1105587","journal-title":"Front Oncol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2017.01.013","article-title":"Pretreatment neutrophil-to-lymphocyte ratio as a marker of outcomes in nivolumab-treated patients with advanced non-small-cell lung cancer","volume":"106","author":"Bagley SJ","year":"2017","unstructured":"Bagley SJ, Kothari S, Aggarwal C, et al.. Pretreatment neutrophil-to-lymphocyte ratio as a marker of outcomes in nivolumab-treated patients with advanced non-small-cell lung cancer. Lung Cancer. 2017, 106:1-7. 10.1016\/j.lungcan.2017.01.013","journal-title":"Lung Cancer"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.5306\/wjco.v13.i7.641","article-title":"Necessity of neutrophil-to-lymphocyte ratio monitoring for hypothyroidism using nivolumab in patients with cancer","volume":"13","author":"Gannichida A","year":"2022","unstructured":"Gannichida A, Nakazawa Y, Kageyama A, Utsumi H, Kuwano K, Kawakubo T. Necessity of neutrophil-to-lymphocyte ratio monitoring for hypothyroidism using nivolumab in patients with cancer. World J Clin Oncol. 2022, 13:641-51. 10.5306\/wjco.v13.i7.641","journal-title":"World J Clin Oncol"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1234142","article-title":"Neutrophil to Lymphocyte ratio as a predictor for immune-related adverse events in cancer patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis","volume":"14","author":"Zhang W","year":"2023","unstructured":"Zhang W, Tan Y, Li Y, Liu J. Neutrophil to Lymphocyte ratio as a predictor for immune-related adverse events in cancer patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis. Front Immunol. 2023, 14:1234142. 10.3389\/fimmu.2023.1234142","journal-title":"Front Immunol"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-023-08097-4","article-title":"Factors associated with early discontinuation of anamorelin in patients with cancer-associated cachexia","volume":"31","author":"Tsukiyama I","year":"2023","unstructured":"Tsukiyama I, Iwata T, Takeuchi T, et al.. Factors associated with early discontinuation of anamorelin in patients with cancer-associated cachexia. Support Care Cancer. 2023, 31:621. 10.1007\/s00520-023-08097-4","journal-title":"Support Care Cancer"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-81195-3","article-title":"Early administration of anamorelin improves cancer cachexia in gastrointestinal cancer patients: an observational study","volume":"14","author":"Matsumoto T","year":"2024","unstructured":"Matsumoto T, Cho S, Nakasya A, Nagai H, Satake H, Yasui H. Early administration of anamorelin improves cancer cachexia in gastrointestinal cancer patients: an observational study. Sci Rep. 2024, 14:30017. 10.1038\/s41598-024-81195-3","journal-title":"Sci Rep"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-023-08206-3","article-title":"Systemic inflammation adversely affects response to anamorelin in patients with pancreatic cancer","volume":"31","author":"Tsunematsu M","year":"2023","unstructured":"Tsunematsu M, Uwagawa T, Onda S, et al.. Systemic inflammation adversely affects response to anamorelin in patients with pancreatic cancer. Support Care Cancer. 2023, 31:732. 10.1007\/s00520-023-08206-3","journal-title":"Support Care Cancer"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-023-07576-y","article-title":"Predictors of response to anamorelin in gastrointestinal cancer patients with cachexia: a retrospective study","volume":"31","author":"Iwai N","year":"2023","unstructured":"Iwai N, Sakai H, Oka K, et al.. Predictors of response to anamorelin in gastrointestinal cancer patients with cachexia: a retrospective study. Support Care Cancer. 2023, 31:115. 10.1007\/s00520-023-07576-y","journal-title":"Support Care Cancer"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1007\/s11912-024-01549-y","article-title":"Anamorelin for the treatment of cancer anorexia-cachexia syndrome","volume":"26","author":"Dev R","year":"2024","unstructured":"Dev R, Amano K, Naito T, Del Fabbro E. Anamorelin for the treatment of cancer anorexia-cachexia syndrome. Curr Oncol Rep. 2024, 26:762-72. 10.1007\/s11912-024-01549-y","journal-title":"Curr Oncol Rep"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdv546","article-title":"Pre-treatment lymphocytopaenia is an adverse prognostic biomarker in muscle-invasive and advanced bladder cancer","volume":"27","author":"Joseph N","year":"2016","unstructured":"Joseph N, Dovedi SJ, Thompson C, et al.. Pre-treatment lymphocytopaenia is an adverse prognostic biomarker in muscle-invasive and advanced bladder cancer. Ann Oncol. 2016, 27:294-9. 10.1093\/annonc\/mdv546","journal-title":"Ann Oncol"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1002\/ncp.10588","article-title":"The use of visceral proteins as nutrition markers: an ASPEN position paper","volume":"36","author":"Evans DC","year":"2021","unstructured":"Evans DC, Corkins MR, Malone A, Miller S, Mogensen KM, Guenter P, Jensen GL. The use of visceral proteins as nutrition markers: an ASPEN position paper. Nutr Clin Pract. 2021, 36:22-8. 10.1002\/ncp.10588","journal-title":"Nutr Clin Pract"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1177\/0148607115621863","article-title":"Guidelines for the provision and assessment of nutrition support therapy in the adult critically Ill patient: Society of Critical Care Medicine (SCCM) and American Society for Parenteral and Enteral Nutrition (A.S.P.E.N.)","volume":"40","author":"McClave SA","year":"2016","unstructured":"McClave SA, Taylor BE, Martindale RG, et al.. Guidelines for the provision and assessment of nutrition support therapy in the adult critically Ill patient: Society of Critical Care Medicine (SCCM) and American Society for Parenteral and Enteral Nutrition (A.S.P.E.N.). JPEN J Parenter Enteral Nutr. 2016, 40:159-211. 10.1177\/0148607115621863","journal-title":"JPEN J Parenter Enteral Nutr"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbamcr.2014.05.014","article-title":"Cytokines and chemokines: at the crossroads of cell signalling and inflammatory disease","volume":"1843","author":"Turner MD","year":"2014","unstructured":"Turner MD, Nedjai B, Hurst T, Pennington DJ. Cytokines and chemokines: at the crossroads of cell signalling and inflammatory disease. Biochim Biophys Acta. 2014, 1843:2563-82. 10.1016\/j.bbamcr.2014.05.014","journal-title":"Biochim Biophys Acta"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/330241-significance-of-neutrophil-to-lymphocyte-ratio-in-predicting-the-efficacy-of-anamorelin-for-cancer-cachexia","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,21]],"date-time":"2025-01-21T23:58:59Z","timestamp":1737503939000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/330241-significance-of-neutrophil-to-lymphocyte-ratio-in-predicting-the-efficacy-of-anamorelin-for-cancer-cachexia"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,21]]},"references-count":30,"URL":"https:\/\/doi.org\/10.7759\/cureus.77795","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1,21]]}}}